Acumen Pharmaceuticals Inc [ABOS] stock prices are up 7.36% to $1.75 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABOS shares have gain 12.18% over the last week, with a monthly amount drifted -2.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acumen Pharmaceuticals Inc [NASDAQ: ABOS] stock has seen the most recent analyst activity on July 26, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $7. Previously, Deutsche Bank started tracking the stock with Buy rating on December 12, 2023, and set its price target to $8. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $13 on May 18, 2023. BTIG Research initiated its recommendation with a Buy and recommended $15 as its price target on July 15, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on June 30, 2022, and assigned it a price target of $15. In a note dated January 21, 2022, BofA Securities upgraded an Buy rating on this stock and revised its target price from $16 to $14.
The stock price of Acumen Pharmaceuticals Inc [ABOS] has been fluctuating between $1.53 and $5.09 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Acumen Pharmaceuticals Inc [NASDAQ: ABOS] shares were valued at $1.75 at the most recent close of the market. An investor can expect a potential return of 300.0% based on the average ABOS price forecast.
Analyzing the ABOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -320.37%, Pretax Profit Margin comes in at -281.63%, and Net Profit Margin reading is -281.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.33 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6167 points at the first support level, and at 1.4835 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8466, and for the 2nd resistance point, it is at 1.9433.
Ratios To Look Out For
It’s worth pointing out that Acumen Pharmaceuticals Inc [NASDAQ:ABOS]’s Current Ratio is 10.43. Also, the Quick Ratio is 10.43, while the Cash Ratio stands at 1.67.
Transactions by insiders
Recent insider trading involved Meisner Derek M, Officer, that happened on Jan 21 ’25 when 3418.0 shares were purchased. Officer, Siemers Eric completed a deal on Jan 21 ’25 to buy 3219.0 shares. Meanwhile, Officer Barton Russell bought 2914.0 shares on Jan 21 ’25.
